Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-104-4 | CAS number: 60207-90-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Aug 2010 to 23 Sep 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Version / remarks:
- 2008
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- December 2002
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- no
Test material
- Reference substance name:
- 1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole
- EC Number:
- 262-104-4
- EC Name:
- 1-[[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl]-1H-1,2,4-triazole
- Cas Number:
- 60207-90-1
- Molecular formula:
- C15H17Cl2N3O2
- IUPAC Name:
- 1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: RjHan:WI
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Females nulliparous and non-pregnant: yes
- Age at study initiation: Young adult rats, 8-11 weeks old
- Weight at study initiation: 189 - 230 g
- Housing: Individual caging in type II polypropylene/polycarbonate cage; lignocel bedding for laboratory animals was available to animals during the study to allow digging and other normal rodent activities
- Diet: Autoclavable complete feed for rats and mice – breeding and maintenance; ad libitum
- Water: tap water, ad libitum
- Acclimation period: At least 5 days under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study
- Method of randomisation in assigning animals to test and control groups: Selected by hand at time of delivery
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3 °C
- Humidity: 30 - 70 %
- Air changes: 15-20 air exchanges/hour
- Photoperiod: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
IN-LIFE DATES: 24 Aug 2010 to 23 Sep 2010
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 2%
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 2 %
- Batch no.: 1414646
- Amount of vehicle: 10 mL/kg bw
DOSAGE PREPARATION: test substance was formulated for treatment doses at 175, 550 and 2000 mg/kg (dose volume of 10 mL/kg). The test substance was formulated in 2% CMC. - Doses:
- 175, 550 and 2000 mg/kg
- No. of animals per sex per dose:
- 175 mg/kg: 1 animal;
550 mg/kg: 3 animals;
2000 mg/kg: 2 animals - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: surviving animals were observed individually after dosing at 30 minutes, 1, 2, 3, 4, and 6
hours after dosing and once each day for 14 days thereafter; body weights were recorded on Day -1 and Days 0 (beginning of the experiment) 7 and 14 (surviving animals)
- Necropsy of survivors performed: yes
- Clinical signs including body weight : individual observations were performed on the skin and fur, eyes and mucous membranes and also respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern; particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
- Other examinations performed: All animals were subjected to macroscopic examination. Surviving animals were exsanguinated under pentobarbital anaesthesia. After examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs were observed. All gross pathological changes were recorded for each animal on the post mortem record sheets.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 550 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test substance caused mortalities at 2000 mg/kg bw (2/2) and at 550 mg/kg bw (1/3). No deaths occurred in any animals treated at 175 mg/kg bw.
- Clinical signs:
- other: Clinical signs including decreased activity, prone position, incoordination, lateral position and hunched back were observed in both animals treated at 2000 mg/kg bw. Additionally one animal dosed at 2000 mg/kg showed decreased body temperature and noisy
- Other findings:
- No treatment related macroscopic findings were observed. Macroscopic findings were seen in animals dosed at 2000 mg/kg and 550 mg/kg. These findings included dark/red discoloration and/or non-collapsing of the lungs. Additionally, dark grey foci in the lungs was observed in one animal dosed at 550 mg/kg. No findings were observed either the other animal dosed at 550 mg/kg bw or in the animal dosed at 175 mg/kg bw.
Any other information on results incl. tables
Table 2. Acute oral toxicity of the test substance in the rat, application scheme and mortality data
Dose (mg/kg body weight) |
Volume given (mL/kg body weight) |
Survival |
2000 |
10 |
Killed on day 1 |
550 |
10 |
Survived |
2000 |
10 |
Found dead (day 2) |
550 |
10 |
Found dead (day 2) |
175 |
10 |
Survived |
550 |
10 |
Survived |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Under the conditions of this study performed in compliance with GLP and following the OECD 425 guideline, the acute oral median lethal dose (LD50) of the test subtance was calculated to be 550 mg/kg bw in female RjHan:WI rats.
- Executive summary:
In the study performed in compliance with GLP and following the OECD 425 guideline a single oral (gavage) dose was administered followed by a 14 day observation period. The animals were fasted overnight prior to treatment. Animals were weighed before dosing and food was returned 3 hours after dosing. Single animals were dosed sequentially at no less than 24 hour intervals. The time intervals between dosing were determined by the onset, duration and severity of toxic signs. Limit test was not performed. The starting dose of the main test was 2000 mg/kg. Surviving animals were observed individually after dosing at 30 minutes, 1, 2, 3, 4 and 6 hours post treatment and once each day for 14 days thereafter. Body weight was measured on Day -1 and just before treatment and weekly after. All surviving animals were examined macroscopically at the end of the study.
Test substance caused mortalities at 2000 mg/kg bw (2/2) and at 550 mg/kg bw (1/3). No deaths occurred in any animals treated at 175 mg/kg bw. Clinical signs including decreased activity, prone position, incoordination, lateral position and hunched back were observed in both animals treated at 2000 mg/kg bw. Additionally, one animal dosed at 2000 mg/kg showed decreased body temperature and noisy respiration. Clinical signs were also observed in animals treated at 550 mg/kg bw. These included decreased activity (3/3), incoordination (3/3), hunched back (2/3), piloerection (2/3), lateral position (2/3) and decreased body temperature (2/3). No clinical signs were observed in the animal dosed at 175 mg/kg. Body weight and body weight changes of the surviving animals during the study showed no indication of a treatment-related effect. No treatment related macroscopic findings were observed in this study.
Under the conditions of this study, the acute oral median lethal dose (LD50) of the test substance was calculated to be 550 mg/kg bw in female RjHan:WI rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.